Restricted accessResearch articleFirst published online 2011-07
Induced Pluripotent Stem Cells Expressing Elevated Levels of Sox-2,Oct-4,and Klf-4 Are Severely Reduced in Their Differentiation from Mesodermal to Hematopoietic Progenitor Cells
Induced pluripotent stem (iPS) cells have been generated from bone marrow (BM) hematopoietic progenitor cells by ectopic expression of Sox-2, Oct-4, and Klf-4 with the hope that they may differentiate more efficiently than embryonic stem (ES) cells in vitro into hematopoietic cell lineages because of their epigenetic memory. An in vitro culture system has been standardized to allow a quantitative assessment of the capacities of different ES, BM-derived iPS, and fibroblast-derived iPS cell lines developing to erythroid, myeloid, and lymphoid cell lineages. Surprisingly, the efficiency to differentiate BM-derived iPS cells to hematopoietic cells in vitro is severely reduced compared with ES cells and fibroblast-derived iPS cells. Undifferentiated as well as differentiated stages of the BM-derived iPS lines express elevated mRNA levels of the transcription factors Sox-2, Oct-4, and Klf-4 with which the iPS cells have been transduced. Overexpression of the transcription factors inhibits development of Flk-1+ mesodermal to CD45+ hematopoietic progenitors. The overexpression of Sox-2 appears to be inversely related to hematogenic potency. These results suggest that iPS cell generation with the aim of developing hematopoietic cells should be controlled and selected for low levels of transduced Sox-2, Oct-4, and Kfl-4 expression.
Get full access to this article
View all access options for this article.
References
1.
AntonchukJ, SauvageauG, HumphriesRK. 2001. HOXB4 overexpression mediates very rapid stem cell regeneration and competitive hematopoietic repopulation. Exp Hematol, 29:1125–1134.
StadtfeldM, MaheraliN, BreaultDT, HochedlingerK. 2008. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell, 2:230–240.
12.
TakahashiK, YamanakaS. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126:663–676.
13.
WernigM, MeissnerA, ForemanR, BrambrinkT, KuM, HochedlingerK, BernsteinBE, JaenischR. 2007. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature, 448:318–324.
14.
MikkelsenTS, HannaJ, ZhangX, KuM, WernigM, SchorderetP, BernsteinBE, JaenischR, LanderES, MeissnerA. 2008. Dissecting direct reprogramming through integrative genomic analysis. Nature, 454:49–55.
Schenke-LaylandK, RhodesKE, AngelisE, ButylkovaY, Heydarkhan-HagvallS, GekasC, ZhangR, GoldhaberJI, MikkolaHK, PlathK, MacLellanWR. 2008. Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells, 26:1537–1546.
23.
GrigoriadisAE, KennedyM, BozecA, BruntonF, StenbeckG, ParkIH, WagnerEF, KellerGM. 2010. Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood, 115:2769–2776.
24.
NakanoT, KodamaH, HonjoT. 1994. Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science, 265:1098–1101.
25.
NishikawaS, OgawaM, NishikawaS, KunisadaT, KodamaH. 1988. B lymphopoiesis on stromal cell clone: stromal cell clones acting on different stages of B cell differentiation. Eur J Immunol, 18:1767–1771.
26.
LiE, BestorTH, JaenischR. 1992. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell, 69:915–926.
27.
KontgenF, SussG, StewartC, SteinmetzM, BluethmannH. 1993. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int Immunol, 5:957–964.
28.
KarasuyamaH, MelchersF. 1988. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol, 18:97–104.
29.
WinklerTH, MelchersF, RolinkAG. 1995. Interleukin-3 and interleukin-7 are alternative growth factors for the same B-cell precursors in the mouse. Blood, 85:2045–2051.
30.
RolinkA, MelchersF, AnderssonJ. 1996. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity, 5:319–330.
31.
KitamuraT, KoshinoY, ShibataF, OkiT, NakajimaH, NosakaT, KumagaiH. 2003. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol, 31:1007–1014.
32.
MoritaS, KojimaT, KitamuraT. 2000. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther, 7:1063–1066.
33.
DoetschmanTC, EistetterH, KatzM, SchmidtW, KemlerR. 1985. The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J Embryol Exp Morphol, 87:27–45.
34.
WilesMV, KellerG. 1991. Multiple hematopoietic lineages develop from embryonic stem (ES) cells in culture. Development, 111:259–267.
RuedlC, KhamenehHJ, KarjalainenK. 2008. Manipulation of immune system via immortal bone marrow stem cells. Int Immunol, 20:1211–1218.
38.
O'ConnorMD, KardelMD, IosfinaI, YoussefD, LuM, LiMM, VercauterenS, NagyA, EavesCJ. 2008. Alkaline phosphatase-positive colony formation is a sensitive, specific, and quantitative indicator of undifferentiated human embryonic stem cells. Stem Cells, 26:1109–1116.
39.
NeriT, MontiM, RebuzziniP, MericoV, GaragnaS, RediCA, ZuccottiM. 2007. Mouse fibroblasts are reprogrammed to Oct-4 and Rex-1 gene expression and alkaline phosphatase activity by embryonic stem cell extracts. Cloning Stem Cells, 9:394–406.
40.
MitsuiK, TokuzawaY, ItohH, SegawaK, MurakamiM, TakahashiK, MaruyamaM, MaedaM, YamanakaS. 2003. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell, 113:631–642.
41.
EvansMJ, KaufmanMH. 1981. Establishment in culture of pluripotential cells from mouse embryos. Nature, 292:154–156.
TrapaniJA, SmythMJ. 2002. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol, 2:735–747.
44.
EichmannA, CorbelC, NatafV, VaigotP, BreantC, Le DouarinNM. 1997. Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc Natl Acad Sci U S A, 94:5141–5146.
45.
MillauerB, Wizigmann-VoosS, SchnurchH, MartinezR, MollerNP, RisauW, UllrichA. 1993. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72:835–846.
46.
FerkowiczMJ, StarrM, XieX, LiW, JohnsonSA, ShelleyWC, MorrisonPR, YoderMC. 2003. CD41 expression defines the onset of primitive and definitive hematopoiesis in the murine embryo. Development, 130:4393–4403.
47.
LiW, FerkowiczMJ, JohnsonSA, ShelleyWC, YoderMC. 2005. Endothelial cells in the early murine yolk sac give rise to CD41-expressing hematopoietic cells. Stem Cells Dev, 14:44–54.
48.
MikkolaHK, FujiwaraY, SchlaegerTM, TraverD, OrkinSH. 2003. Expression of CD41 marks the initiation of definitive hematopoiesis in the mouse embryo. Blood, 101:508–516.
49.
KabrunN, BuhringHJ, ChoiK, UllrichA, RisauW, KellerG. 1997. Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development, 124:2039–2048.
50.
OkuyamaH, TsunetoM, YamaneT, YamazakiH, HayashiS. 2003. Discrete types of osteoclast precursors can be generated from embryonic stem cells. Stem Cells, 21:670–680.
51.
VarasF, BernardA, BuerenJA. 1998. Restrictions in the stem cell function of murine bone marrow grafts after ex vivo expansion of short-term repopulating progenitors. Exp Hematol, 26:100–109.
52.
NishiN, OsawaM, IshikawaR, NishikawaM, TsumuraH, InoueH, SudoT. 1995. Hematopoietic stem cells found in lineage-positive subsets in the bone marrow of 5-fluorouracil-treated mice. Stem Cells, 13:517–523.
53.
ChoiKD, YuJ, Smuga-OttoK, SalvagiottoG, RehrauerW, VodyanikM, ThomsonJ, SlukvinI. 2009. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells, 27:559–567.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
